Insider Transactions in Q2 2021 at Prelude Therapeutics Inc (PRLD)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-38.65%
|
$465,000
$31.57 P/Share
|
|
Jun 07
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
May 25
2021
|
Brian Piper Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,333
-69.44%
|
$283,322
$34.79 P/Share
|
|
May 25
2021
|
Brian Piper Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+50.0%
|
$8,333
$1.89 P/Share
|
|
May 07
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.85%
|
$410,000
$41.1 P/Share
|
|
May 07
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.18%
|
$10,000
$1.43 P/Share
|
|
May 05
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-71.06%
|
$600,000
$40.24 P/Share
|
|
May 05
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Apr 29
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
3,223
-87.89%
|
$128,920
$40.29 P/Share
|
|
Apr 29
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
3,223
+46.78%
|
$3,223
$1.89 P/Share
|
|
Apr 29
2021
|
Christopher Pierce EVP and Chief of Business Oper |
SELL
Open market or private sale
|
Direct |
3,295
-46.77%
|
$131,800
$40.29 P/Share
|
|
Apr 29
2021
|
Christopher Pierce EVP and Chief of Business Oper |
BUY
Exercise of conversion of derivative security
|
Direct |
3,295
+31.87%
|
$3,295
$1.89 P/Share
|
|
Apr 27
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,000
-73.62%
|
$875,000
$35.48 P/Share
|
|
Apr 27
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$25,000
$1.89 P/Share
|
|
Apr 19
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,000
-92.0%
|
$775,000
$31.05 P/Share
|
|
Apr 19
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
$25,000
$1.89 P/Share
|
|
Apr 08
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,617
-46.1%
|
$365,446
$38.36 P/Share
|
|
Apr 08
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,617
+50.0%
|
$9,617
$1.89 P/Share
|
|
Apr 08
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
100
-18.38%
|
$4,000
$40.0 P/Share
|
|
Apr 08
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+15.53%
|
$100
$1.89 P/Share
|
|
Apr 08
2021
|
Christopher Pierce EVP and Chief of Business Oper |
SELL
Open market or private sale
|
Direct |
200
-5.06%
|
$8,000
$40.0 P/Share
|
|
Apr 08
2021
|
Christopher Pierce EVP and Chief of Business Oper |
BUY
Grant, award, or other acquisition
|
Direct |
200
+4.82%
|
$200
$1.89 P/Share
|
|
Apr 08
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,630
-0.66%
|
$175,940
$38.31 P/Share
|
|
Apr 08
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,630
+2.54%
|
$4,630
$1.43 P/Share
|
|
Apr 07
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,383
-76.98%
|
$599,937
$39.36 P/Share
|
|
Apr 07
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,383
+50.0%
|
$15,383
$1.89 P/Share
|
|
Apr 07
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
1,000
-69.25%
|
$40,000
$40.04 P/Share
|
|
Apr 07
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+40.92%
|
$1,000
$1.89 P/Share
|
|
Apr 07
2021
|
Christopher Pierce EVP and Chief of Business Oper |
SELL
Open market or private sale
|
Direct |
828
-18.09%
|
$33,120
$40.08 P/Share
|
|
Apr 07
2021
|
Christopher Pierce EVP and Chief of Business Oper |
BUY
Grant, award, or other acquisition
|
Direct |
828
+15.32%
|
$828
$1.89 P/Share
|
|
Apr 07
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,370
-2.78%
|
$599,430
$39.65 P/Share
|
|
Apr 07
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,370
+7.55%
|
$15,370
$1.43 P/Share
|